###### Strengths and limitations of this study

-   This is the first study that evaluates the adherence of systematic reviews (SRs) in nursing journals to Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Assessing the Methodological Quality of Systematic Reviews.

-   SRs published in non-nursing journals were not captured.

-   Only reviews published in 2014 were included.

-   Assessments were conducted based on the subjective evaluation of the reviews.

Background {#s1}
==========

As an important tool for summarising evidence, systematic reviews (SRs) can help healthcare professionals to evaluate the beneficial and harmful effects of behaviours and interventions by providing a basis to develop and revise clinical practice guidelines.[@R1] However, SRs often poorly report key information and inevitably diminishes their soundness of scientific evidence.[@R2] [@R3] A previous study had empirically evaluated published reviews and determined that such reviews failed to meet the eight explicit scientific criteria, developed based on established guidelines,[@R4] [@R5] which were purpose, data identification, data selection, validity assessment, qualitative synthesis, quantitative synthesis, summary and future directions.[@R6] Another study reported that published SR only fulfilled approximately one-third of the authors\' predefined 23 characteristics, including 8 items in design, 2 in combinability, 4 in control of bias, 4 in statistical analysis, 3 in the sensitivity analysis and 2 in the application of results.[@R7]

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement is an evidence-based minimum set of items for reporting SRs and meta-analyses.[@R1] [@R8] [@R9] This statement focuses on the reporting of reviews that evaluate randomised controlled trials but can also be used for reporting SRs of other types of research. Published in 2009, the PRISMA statement consists of 27 items and a flow chart in which the items pertain to the contents of an SR and meta-analysis (MA), including the title, abstract, methods, results, discussion and funding.[@R1] [@R8] One hundred and seventy-six general and specialty medical journals have formally endorsed the PRISMA statement and requested contributors follow PRISMA while reporting their SR. The list of the journals can be found in the PRISMA website.[@R9] Some journals only recommend PRISMA to their contributors through 'Instructions for Authors' but do not formally endorse it on the PRISMA website.

The PRISMA statement is not the only reporting guideline used in healthcare research. The Consolidated Standards of Reporting Trials (CONSORT)[@R10] is another commonly used guideline for randomised controlled trials. Developed in 1996, this guideline is currently endorsed by 585 general and specialty journals.[@R11] Many studies have examined the endorsement and adherence of medical specialties to CONSORT,[@R10] [@R12] but only a few have performed so in accordance with the PRISMA statement.[@R16]

The PRISMA statement was published 6 years ago; thus, the time is appropriate to assess its impact on the quality of SRs in the nursing literature. The aim of this study is twofold: (1) to investigate the number of nursing journals that have endorsed or recommended the use of the PRISMA statement for reporting SRs and (2) to examine the adherence of published SRs to the statement.

Method and materials {#s2}
====================

Study design {#s2a}
------------

A cross-sectional study was conducted by evaluating published SRs in nursing journals extracted from three scholarly databases.

Inclusion and exclusion criteria {#s2b}
--------------------------------

Articles included in this study are self-proclaimed SRs or include the term 'meta-analyses' in the title or abstract, or both. Methodology papers, commentaries or letters on SRs or meta-analyses were excluded.

Search strategy {#s2c}
---------------

Nursing journals were first identified from the 'Nursing Studies' category in the Journal Citation Reports Science Edition 2013,[@R20] which was the latest available version in early 2015. The selected journals were divided into two groups according to whether they recommend the PRISMA in their 'Instruction for Authors'.

After classification, a database search was performed for each group of journals to identify the SRs; the final search was conducted in May 2015. Three databases, namely Cumulative Index of Nursing and Allied Health Literature, PubMed and Web of Science, were used in the search combined with journal titles and keywords. The keyword search included 'systematic review', 'meta\*analys\*' or 'pooled analys\*', which were adopted to identify SRs and meta-analyses in another study.[@R21] Only articles published in the whole 2014, the latest available year, were included in this study. The results from each database were imported to EndNote X7, and duplicate records were removed.

Selection of articles {#s2d}
---------------------

The titles and abstracts of the articles were screened by two independent reviewers (ie, KKHL and PK) to select the eligible ones. Full texts of the articles were downloaded for further evaluation in case there were disagreements in the selection. Disagreements were then solved by consensus. When incongruities persisted, a third review author (WWST) was consulted.

Four-digit random numbers, generated using the RandBetween function in MS Excel, were assigned to the selected studies. The studies were sorted in ascending order according to the random numbers.

Outcomes {#s2e}
--------

The quality of reporting of the included reviews was assessed according to their adherence to the PRISMA statement, while the quality of the reviews was assessed using the Assessing the Methodological Quality of Systematic Reviews (AMSTAR).[@R22] AMSTAR is a validated and reliable instrument that helps users to differentiate SRs in terms of their methodological quality and expert consensus. Details of AMSTAR are reported elsewhere.[@R23] All studies were assessed by two independent reviewers (KKHL and PK), and discrepancies in the assessments were resolved by joint discussion. The adherence level for each item was rated as either 1 (Yes), 2 (No) or 3 (Not Applicable). The main outcomes of the study were overall adherence to the PRISMA and AMSTAR checklists.

Sample size consideration {#s2f}
-------------------------

Considering the 95% CIs reported in Table 1 of Panic *et al*\'s,[@R16] we back-calculated the SD for each group (ranging from 15.0 to 18.0) and took the smallest one for our sample size calculation. Given that the largest difference between the two groups reported by Panic *et al* was 8, we further assumed 10 to be a meaningful difference in the mean total adherence between the two groups of journals to the PRISMA statement in our study. Therefore, a sample size of 37 articles per group was needed to detect the difference at 5% significance level and 80% power.[@R24] The first 37 studies from the magnitude of the random numbers in each group were selected for evaluation.

Statistical data analyses {#s2g}
-------------------------

Frequencies, percentages, median and IQR were used to summarise the findings. χ^2^ test was performed to examine the adherence of the items to the PRISMA statement and AMSTAR guidelines. Expressed as the percentage, the difference of the total adherence between the groups was examined through the Mann-Whitney U test. All statistical tests were conducted using IBM SPSS Statistics 24, with 5% significance level.

Results {#s3}
=======

A total of 107 journals were identified from the Journal Citation Reports (see online [supplementary table S1](#SM1){ref-type="supplementary-material"}), and 30 (28.0%) of them recommended (20 journals) or required (10 journals) authors to follow the PRISMA statement for submitting SRs or meta-analyses. All journals were divided into two groups, in which Group A comprised journals with PRISMA recommendation/requirement (n=30) and Group B comprised those without (n=77). Database search was performed in which 512 and 558 articles were identified for Groups A and B, respectively. After duplicate articles and those from inappropriate journals (ie, those with names similar to the identified journals; eg, '*Heart and Lung*' is a journal under the nursing category while '*Heart, Lung and Vessels*' is not) were removed, 462 and 487 articles in the two groups were evaluated for eligibility by title and abstract screening. Finally, 119 and 124 articles were included in Groups A and B, respectively. A total of 37 articles were randomly selected from the final number of selected articles ([figure 1](#BMJOPEN2016013905F1){ref-type="fig"}; a full list of the 74 articles is available in online [supplementary table S2](#SM1){ref-type="supplementary-material"}). [Table 1](#BMJOPEN2016013905TB1){ref-type="table"} summarises the characteristics of all 74 studies.
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###### 

Characteristics of the 74 reviews included in this study

                                                           Group A      Group B
  -------------------------------------------------------- ------------ --------------
  *First author\'s country of affiliation (p~Chi~=0.06)*                
  Australia and Asia                                       14 (37.8%)   7 (18.9%)
   Australia                                               6            3
   China                                                   1            2
   Iran                                                    1            0
   Pakistan                                                0            1
   New Zealand                                             1            0
   Singapore                                               1            0
   South Korea                                             2            1
   Taiwan                                                  2            0
  Europe                                                   11 (29.7%)   8 (21.6%)
   Belgium                                                 2            1
   Demark                                                  0            1
   Finland                                                 3            0
   Germany                                                 1            1
   Norway                                                  1            1
   Sweden                                                  0            2
   UK and Ireland                                          4            2
  America                                                  12 (32.4%)   22 (59.5%)
   Brazil                                                  4            0
   Canada                                                  0            2
   USA                                                     8            20
  *Topic of the review (p~Chi~=0.253)*                                  
  Diseases-related                                         24 (64.8%)   26 (70.2%)
   Cardiology                                              1            4
   Endocrinology                                           2            0
   Geriatric                                               2            4
   Maternal and child health                               4            1
   Mental health                                           2            2
   Oncology                                                3            8
   Oral health                                             2            0
   Paediatric and adolescent health                        2            2
   Surgery                                                 1            3
   Others                                                  5            2
  Nursing education or practice                            10 (27.0%)   5 (13.5%)
  Others                                                   3 (8.1%)     6 (16.2%)
  Number of papers included in the review (p~Chi~=0.517)                
   1--10                                                   9 (24.3%)    12 (32.4%)
   11--20                                                  17 (45.7%)   12 (32.4%)
   21 or more                                              11 (29.7%)   12 (32.4%)\*
  Median (range)                                           15 (3-75)    12.5 (1-137)

\*One review did not state the number of papers included in the review.

![Flow chart for studies selection.](bmjopen2016013905f01){#BMJOPEN2016013905F1}

In terms of the affiliation of the first author, 14 (37.4%), 11 (29.7%) and 12 (32.4%) articles in Group A and 7 (18.9%), 8 (21.6%) and 22 (59.5%) articles in Group B were from Australia and Asia, Europe and America, respectively. No significant difference in the distribution of author affiliations was detected. The disease-related topics have contributed to 24 (64.8%) articles in Group A and 26 (70.2%) articles in Group B. [Table 1](#BMJOPEN2016013905TB1){ref-type="table"} illustrates the breakdown of these diseases. The median numbers of articles included in each review were 15 in Group A and 12.5 in Group B. In Group A, 12 (32.4%) reported that they followed PRISMA guideline, while only 8 (21.6%) articles in Group B did (p=0.295).

[Table 2](#BMJOPEN2016013905TB2){ref-type="table"} compares the adherence of the groups on the individual items of the PRISMA statement. The median of the overall adherence of the reviews to the 27 items to the PRISMA checklist was 55.6% (IQR: 48.2--61.1%) for Group A and 59.3% (IQR: 48.2--64.8%) for Group B with no significant difference (p~MW~=0.617). The median adherence of Group A to the PRISMA was 64.9% (17.6--92.3%) and that of Group B was 73.7% (IQR: 59.5--94.6%) after withdrawing those 'not applicable' items in computation with no significant difference (p~MW~=0.576).

###### 

Summary table for PRISMA comparison

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Items                                                                                                                                                                                                                                                                                                           Group A               Group B                                                                   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------- --------------------- ------------ ------------ ------------ ------------ -------
  1. Identify the report as a systematic review, meta-analysis or both in title                                                                                                                                                                                                                                   30 (81.1%)            7 (18.9%)             0 (0.0%)     29 (78.4%)   8 (21.6%)    0 (0.0%)     0.727

  2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number   37 (100%)             0 (0.0%)              0 (0.0%)     37 (100%)    0 (0.0%)     0 (0.0%)     1

  3. Describe the rationale for the review in the context of what is already known                                                                                                                                                                                                                                37 (100%)             0 (0.0%)              0 (0.0%)     37 (100%)    0 (0.0%)     0 (0.0%)     1

  4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes and study design (PICOS)                                                                                                                                                     37 (100%)             0 (0.0%)              0 (0.0%)     35 (94.6%)   2 (5.4%)     0 (0.0%)     0.152

  5. Indicate if a review protocol exists, if and where it can be accessed (eg, Web address), and, if available, provide registration information\                                                                                                                                                                1 (2.7%)              36 (97.3%)            0 (0.0%)     1 (2.7%)     36 (97.3%)   0 (0.0%)     1
  including registration number                                                                                                                                                                                                                                                                                                                                                                                   

  6. Specify study characteristics (eg, PICOS, length of follow-up) and report characteristics (eg, years considered, language, publication status) used as criteria for eligibility, giving rationale                                                                                                            36 (97.3%)            1 (2.7%)              0 (0.0%)     34 (91.9%)   3 (8.1%)     0 (0.0%)     0.304

  7. Describe all information sources (eg, databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched                                                                                                                                      37 (100%)             0 (0.0%)              0 (0.0%)     36 (97.3%)   1 (2.7%)     0 (0.0%)     0.314

  8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated                                                                                                                                                                                 5 (13.5%)             32 (86.5%)            0 (0.0%)     4 (10.8%)    33 (89.2%)   0 (0.0%)     0.722

  9. State the process for selecting studies (ie, screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis)                                                                                                                                                       37 (100%)             0 (0.0%)              0 (0.0%)     35 (94.6%)   2 (5.4%)     0 (0.0%)     0.152

  10. Describe method of data extraction from reports (eg, piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators                                                                                                                                     14 (37.8%)            23 (62.2)             0 (0.0%)     22 (59.4%)   15 (40.6%)   0 (0.0%)     0.063

  11. List and define all variables for which data were sought (eg, PICOS, funding sources) and any assumptions and simplifications made                                                                                                                                                                          24 (64.9%)            13 (35.1%)            0 (0.0%)     30 (81.1%)   7 (18.9%)    0 (0.0%)     0.116

  12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was performed at the study or outcome level), and how this information is to be used in any data synthesis                                                                                  23 (62.2%)            14 (37.8%)            0 (0.0%)     22 (59.5%)   15 (40.6%)   0 (0.0%)     0.812

  13. State the principal summary measures (eg, risk ratio, difference in means)                                                                                                                                                                                                                                  8 (21.6%)             1 (2.7%)              28 (75.7%)   8 (21.6%)    0 (0.0%)     29 (78.4%)   0.601

  14. Describe the methods of handling data and combining results of studies, if performed, including measures of consistency (eg, I2) for each meta-analysis                                                                                                                                                     6 (16.2%)             2 (5.4%)              29 (78.4%)   8 (21.6%)    0 (0.0%)     29 (78.4%)   0.319

  15. Specify any assessment of risk of bias that may affect the cumulative evidence (eg, publication bias, selective reporting within studies)                                                                                                                                                                   3 (8.1%)              5 (13.5%)             29 (78.4%)   4 (10.8%)    4 (10.8%)    29 (78.4%)   0.881

  16. Describe methods of additional analyses (eg, sensitivity or subgroup analyses, meta-regression), if performed, indicating which were prespecified                                                                                                                                                           3 (8.1%)              5 (13.5%)             29 (78.4%)   6 (16.2%)    3 (8.1%)     28 (75.7%)   0.468

  17. Give numbers of studies screened, assessed for eligibility and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram                                                                                                                                               35 (94.6%)            2 (5.4%)              0 (0.0%)     33 (89.2%)   4 (10.8%)    0 (0.0%)     0.394

  18. For each study, present characteristics for which data were extracted (eg, study size, PICOS, follow-up period) and provide the citations                                                                                                                                                                   34 (91.9%)            3 (8.1%)              0 (0.0%)     29 (78.4%)   8 (21.6%)    0 (0.0%)     0.102

  19. Present data on risk of bias of each study and, if available, any outcome-level assessment (see Item 12)                                                                                                                                                                                                    16 (43.2%)            21 (56.8%)            0 (0.0%)     17 (45.9%)   20 (54.1%)   0 (0.0%)     0.815

  20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group and (b) effect estimates and CIs, ideally with a forest plot                                                                                                                  8 (21.6%)             0 (0.0%)              29 (78.4%)   8 (21.6%)    1 (2.7%)     28 (75.7%)   0.601

  21. Present results of each meta-analysis performed, including CIs and measures of consistency                                                                                                                                                                                                                  7 (18.9%)             1 (2.7%)              29 (75.7%)   8 (21.6%)    1 (2.7%)     28 (75.7%)   0.959

  22. Present results of any assessment of risk of bias across studies (see Item 15)                                                                                                                                                                                                                              3 (8.1%)              5 (13.5%)             29 (78.4%)   2 (5.4%)     7 (18.9%)    28 (75.7%)   0.759

  23. Give results of additional analyses, if performed (eg, sensitivity or subgroup analyses, meta-regression (see Item 16))                                                                                                                                                                                     3 (8.1%)              5 (13.5%)             29 (78.4%)   3 (8.1%)     6 (16.2%)    28 (75.7%)   0.947

  24. Summarise the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (eg, healthcare providers, users and policymakers)                                                                                                                             36 (97.3%)            1 (2.7%)              0 (0.0%)     35 (94.6%)   2 (5.4%)     0 (0.0%)     0.557

  25. Discuss limitations at study and outcome level (eg, risk of bias), and at review level (eg, incomplete retrieval of identified research, reporting bias)                                                                                                                                                    25 (67.6%)            12 (32.4%)            0 (0.0%)     27 (73.0%)   10 (27.0%)   0 (0.0%)     0.611

  26. Provide a general interpretation of the results in the context of other evidence, and implications for future research                                                                                                                                                                                      37 (100%)             0 (0.0%)              0 (0.0%)     36 (97.3%)   1 (2.7%)     0 (0.0%)     0.314

  27\. Describe sources of funding for the systematic review and other support (eg, supply of data); role of funders for the systematic review                                                                                                                                                                    25 (67.6%)            12 (32.4%)            0 (0.0%)     27 (73.0%)   10 (27.0%)   0 (0.0%)     0.611

  Overall---median (IQR)                                                                                                                                                                                                                                                                                          55.6% (48.2--61.1%)   59.3% (48.2--64.8%)                                                       

  Overall without counting the NA items---median (IQR)                                                                                                                                                                                                                                                            64.9% (17.6--92.3%)   73.0% (59.5--94.6%)                                                       
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Some of the items in the PRISMA related to statistical analysis or MA may not be appropriate for qualitative reviews or reviews without meta-analyses. Thus, subgroup analysis was conducted by removing the eight items that were not relevant to all SRs (ie, items 13--16 and 20--23). After such removal, the median of the overall adherence of the remaining 19 items became 75% (IQR: 65--80%) for Group A and 80% (IQR: 65--80%) for Group B (p~MN~=0.678).

[Table 3](#BMJOPEN2016013905TB3){ref-type="table"} demonstrates the comparison of the adherence of journals to the individual items of the AMSTAR checklist. The median adherence for the 11 items was 8.1% in Group A and 8.1% in Group B. Only item 6 ('Were the characteristics of the included studies provided?') received an adherence level higher than 50%. The median of the overall adherence of the reviews to the AMSTAR checklist was 18.2% (IQR: 9.1--27.3%) for Group A and 18.2% (IQR: 9.1--18.2%) for Group B with no significant difference (p~MW~=0.494).

###### 

Summary table AMSTAR

                                                                                                         Group A              Group B                                                                 
  ------------------------------------------------------------------------------------------------------ -------------------- -------------------- ------------ ------------ ------------ ----------- ---------
  1. Was an 'a priori' design provided?                                                                  1 (2.7%)             36 (97.3%)           0 (0.0%)     0 (0.0%)     37 (100%)    0 (0.0%)    1.00\^
  2. Was there duplicate study selection and data extraction?                                            6 (16.2%)            31 (83.8%)           0 (0.0%)     6 (16.2%)    31 (83.8%)   0 (0.0%)    1.00\^
  3. Was a comprehensive literature search performed?                                                    8 (27.6%)            29 (78.4%)           0 (0.0%)     7 (18.9%)    30 (81.1%)   0 (0.0%)    0.772
  4. Was the status of publication (ie, grey literature) used as an inclusion criterion?                 5 (13.5%)            32 (86.5%)           0 (0.0%)     3 (8.1%)     34 (91.9%)   0 (0.0%)    0.771
  5. Was a list of studies (included and excluded) provided?                                             0 (0.0%)             37 (100%)            0 (0.0%)     0 (0.0%)     37 (100%)    0 (0.0%)    NA
  6. Were the characteristics of the included studies provided?                                          34 (91.9%)           3 (8.1%)             0 (0.0%)     29 (78.4%)   8 (27.6%)    0 (0.0%)    0.102
  7. Was the scientific quality of the included studies assessed and documented?                         14 (37.8%)           23 (62.2%)           0 (0.0%)     14 (37.8%)   23 (62.2%)   0 (0.0%)    1.00
  8. Was the scientific quality of the included studies used appropriately in formulating conclusions?   3 (8.1%)             34 (91.9%)           0 (0.0%)     5 (13.5%)    32 (86.5%)   0 (0.0%)    0.711\^
  9. Were the methods used to combine the findings of studies appropriate?                               3 (8.1%)             3 (8.1%)             31 (83.7%)   2 (5.4%)     6 (16.2%)    29 (7.8%)   0.531
  10\. Was the likelihood of publication bias assessed?                                                  3 (8.1%)             3 (8.1%)             31 (83.7%)   2 (5.4%)     6 (16.2%)    29 (7.8%)   0.531
  11\. Was the conflict of interest included?                                                            0 (0.0%)             37 (100%)            0 (0.0%)     0 (0.0%)     37 (100%)    0 (0.0%)    NA
  Overall---median (IQR)                                                                                 18.2% (9.1--21.3%)   18.2% (9.1--18.2%)                                                      

\^p-value computed by Fisher\'s exact test.

Discussion {#s4}
==========

Our findings show that 28% (30/107) of nursing journals endorsed or recommended the PRISMA statement in their 'Instruction for Authors'. This percentage is similar to that previously reported for internal and specialty medical journals (27%, 40/146).[@R17] The findings generally conform to the endorsement of other reporting guidelines. For example, a recent study reported that among 15 top nursing journals, 7 (46.7%) promoted the CONSORT statement. The PRISMA website was cross-checked for this study. Among the 107 nursing journals, only 2 formally endorsed the PRISMA, namely the *Journal of the American Academy of Nurse Practitioners* and *Nursing Research*.[@R9]

The median overall adherence of Groups A and B to the 27 items of the PRISMA statement was 55.6% and 59.3%, respectively. Without the eight items on MA, the median adherence of the two groups was 75% and 80%, slightly lower than the values reported for gastroenterology and hepatology journals (83.1--91.1%),[@R16] and radiology journals (83.7%)[@R19] but comparable to those reported for otorhinolaryngology journals.[@R25] One reason was that four items (ie, items 5, 8, 12 and 19) in the guideline obtained a relatively low adherence rating among nursing journals.

Item 5 is about the existence of a research protocol for SRs. This study determined that among the 74 SRs, only 2 (2.7%) mentioned their research protocols. Although research protocol is common or even necessary to obtain ethics approval, a protocol for SRs is less popular not only in nursing research but also in medical research. For example, Panic *et al*[@R16] reported that only 4 (4.4%) out of 90 SRs in gastroenterology and hepatology journals, 15% of SRs in radiology journals[@R19] and 27% of the reviews in orthodontic journals[@R18] mentioned research protocols. Nevertheless, a protocol is important because it prespecifies the objectives and methods of an SR,[@R1] and a well-developed protocol ensures that valuable resources and time can be used appropriately.[@R26] The preparation of a protocol for SR is required for several journals, such as *Cochrane Database for Systematic Reviews*.

Among the 74 SRs, only 9 (12.2%) adhered to item 8 ('Present full electronic search strategy for at least one database') of the PRISMA, although more than 80% of medical journals adhere to this item.[@R18] [@R19] A search strategy is an essential part of a review because it allows interested readers to assess the comprehensiveness and completeness of the search and replicate it.[@R1] Without the full search strategy, readers and reviewers are unable to judge the quality of the search in the review, and the usefulness of such review will diminish.

Items 12 and 19 are related to the assessment of the risks of bias for individual studies, and the adherence of Groups A and B to these items was 60.8% and 44.5%, respectively, though other specialty journals have higher adherence (75%) to these items.[@R16] [@R18] [@R19] Defined as the risk of 'a systematic error or deviation from the truth, in results, or inferences', the risk of bias corresponds to the internal validity of a study.[@R27] Assessing such risk is part of measuring the strength of a body of evidence. Thus, this assessment is a crucial component of SR because it can be used as a threshold for study selection, a guide for qualitative and quantitative syntheses and a basis for interpreting heterogeneous findings.[@R27] The lack of such assessment of the risk of bias may affect the internal validity of research findings.

Although no statistical difference was observed in the adherence between the two groups, the median adherence rate of SRs in Group A was lower than in Group B. As presented in [table 2](#BMJOPEN2016013905TB2){ref-type="table"}, the adherence rates of 16 out of the 27 items in Group A were the same or higher than those in Group B, and the difference of the adherence rate was \>5% only for two items, namely items 10 and 11. Item 10 was the description of the data extraction method, while item 11 was about listing or defining variables. Since data extraction and variables are essential to any study, the authors of the articles would have conducted these steps. However, the authors might have thought these steps were less important and, therefore, did not clearly state them. It also reflects the importance of following a standard guideline to report the findings. In fact, some journals request the authors of SRs and meta-analyses to submit their manuscripts with the PRISMA checklist in which the page numbers for each item should be indicated.

With regard to AMSTAR, 9 out of the 11 items had adherence level lower than 20% except for items 6 and 7. The adherence levels of nursing journals to items 4 ('Was the status of publication (ie, grey literature) used as an inclusion criterion?') and 10 ('Was the likelihood of publication bias assessed?') were low, similar to those of other specialty journals.[@R19] [@R28] Several items, including items 3 ('Was a list of studies (included and excluded) provided?') and 5 ('Was a list of studies (included and excluded) provided?'), also had a relatively low adherence level among nursing journals (\<20%), despite the high adherence to these items by other specialty journals (\>80%).[@R16] [@R18] [@R19] The issue of low AMSTAR score was also reported in other studies.[@R29] [@R30]

The inappropriate conduct or reporting of SRs may be the reason for the comparatively low adherence level to PRISMA and AMSTAR. The proper conduct of SRs entails the application of explicitly predefined systematic approaches to formulate the research question, study the eligibility criteria, develop the search strategy conduct study selection and data extraction, assess the risk of bias or methodological quality of included studies perform data synthesis and analysis and grade the overall quality of evidence.[@R31] Each step requires the application of specific knowledge and skills, but previous nursing curricula have focused mainly on the first few steps.[@R32] Thus, the training of some nursing scholars may not have been adequate for a proper SR,[@R33] which explains why the quality of reviews varies. The adherence level to PRISMA and AMSTAR did not differ with the inclusion of PRISMA in the author information. As only 10 out of 30 journals have adhered to the PRISMA statement, a possibility is that some authors do not adhere to the guidelines if journals only encourage them to do so.

Additionally, although MA has been included in most evidence-based practice modules in nursing curricula, many students fail to completely understand MA statistical techniques or the various important concepts that underpin.[@R34] This study found that 57 out of 74 (∼77%) SRs did not include any meta-analyses, which may have originated from the extremely limited technique to pool data from individual studies. Another possibility is that some topics struggle to synthesise quantitative evidence, such as the review of qualitative studies. However, data pooling is feasible on some topics such as breast feeding and childhood obesity, but the authors in our included studies did not attempt it.[@R35]

Although scholars conduct their reviews properly, important information may still be overlooked if they refuse to follow a guideline. While some nursing journals recommend that authors follow the PRISMA statement for their SRs, the authors can still submit their reviews even when their studies do not follow the PRISMA style. In contrast, many medical journals, including *the British Medical Journal*[@R36] and *Medicine,*[@R37] not only request authors to follow PRISMA but also require them to submit the PRISMA checklist with the corresponding page number for each item to ensure that such reviews are PRISMA-compliant.

Strength and limitation {#s4a}
-----------------------

To the best of our knowledge, this study is the first to evaluate the adherence of SRs in nursing journals to PRISMA and AMSTAR. A systematic approach was adopted to reduce any potential bias in reviewing. This study has several limitations. First, SRs published in non-nursing journals were not captured. For example, an MA, conducted by all nursing faculty in evaluating the beneficial effects of physical activity on cancer survivors,[@R38] published in a medical journal that requested all SRs to be reported according to the PRISMA; therefore, it would expect that the adherence of these papers should be higher and in fact the adherence of this article was 96.3% (ie, 26 out of 27 item). Second, only reviews published in 2014 (the latest available full year) were included, which may introduce bias. Third, the SRs were assessed based on the subjective evaluation of the published reviews; thus, the bias was incompletely ruled out because the quality assessment was conducted by two independent investigators. Fourth, most of the included reviews had no MA; thus, several items in the PRISMA may not be suitable for them. Nevertheless, although a few items were removed from the guideline, the adherence of the reviews in nursing journals was still low compared with that of the reviews in other specialty journals. Finally, we adopted a database search approach instead of hand searching each journal, which could result in overlooking eligible studies. As a sensitivity analysis, hand searching was conducted for two included journals, namely '*Heart and Lung*' and '*Journal of Nursing Research*' to identify potential SRs and/or meta-analyses. In fact, all SRs and/or meta-analyses identified in the hand searching (three in *Heart and Lung* and two in *Journal of Nursing Research*) were also identified in the database search.

In conclusion, the adherence of SRs in nursing journals to PRISMA is comparable to otorhinolaryngology journals but lower than gastroenterology, hepatology and radiology journals. The adherence level of nursing journals to PRISMA does not significantly vary whether they endorse or recommend such guideline. As previous studies suggested, the requirement of following the guidelines in the 'Instructions for Authors' may increase the quality of reporting and methodology.[@R39] [@R40] Thus, nursing journals should require authors to follow PRISMA as their reporting guideline for SRs.
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